REZAFUNGIN:新的考察及市場預測 (∼2030年)

未來幾年，由於全球對治療適應症的廣泛研究和不斷增加的醫療保健支出，念珠菌性敗血症的市場前景將發生變化。這將擴大市場規模，使藥品製造商能夠更擴大滲透到市場中。

本報告提供美國，歐洲5個國家(德國，法國，義大利，西班牙，英國)以及日本等7個主要市場上REZAFUNGIN市場相關之詳細說明，刊載產品的詳細說明，作用機制，投藥和管理，合成途徑，及法規里程碑和其他開發活動的R&D活動相關詳細內容，市場預測，SWOT分析，競爭企業，新的治療方法等相關資訊。

目錄

第1章 藥物概要

• 產品詳細內容
• 作用機制
• 投藥和管理
• 研究開發活動
  • 臨床開發
  • 安全性和有效性
• 其他開發活動

第2章 市場評估

• 主要7個國家市場分析
• 美國市場
• 德國市場
• 法國市場
• 義大利市場
• 西班牙市場
• 英國市場
• 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭企業

第6章 其他的新治療方法

第7章 附錄

第8章 購買選擇的報告

"REZAFUNGIN- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Candidemia in 7 Major Markets. A detailed picture of the REZAFUNGIN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. Rezafungin is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections. Rezafungin's structure and properties have been precisely refined to retain the safety benefits of echinocandin drugs while enhancing its pharmacokinetic and pharmacodynamic properties to create a longer-lasting, next-generation treatment and preventative, capable of addressing even drug-resistant species. The U.S. Food and Drug Administration (FDA) has designated rezafungin as a Qualified Infectious Disease Product (QIDP) and a Fast Track Product for both the treatment of candidemia and invasive candidiasis and for prevention of invasive fungal infections in adults undergoing allogeneic hematopoietic stem cell transplantation. The FDA has also designated rezafungin as an orphan drug for the treatment indication.

Scope of the report:

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around REZAFUNGIN.
• The report contains forecasted sales for REZAFUNGIN till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase II) for Candidemia.
• The report also features the SWOT analysis with analyst insights and key findings of REZAFUNGIN.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REZAFUNGIN Analytical Perspective by DelveInsight

• In-depth REZAFUNGIN Market Assessment

This report provides a detailed market assessment of REZAFUNGIN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• REZAFUNGIN Clinical Assessment

The report provides the clinical trials information of REZAFUNGIN covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

• In the coming years, the market scenario for Candidemia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence REZAFUNGIN dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Candidemia are giving market competition to REZAFUNGIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of REZAFUNGIN.
• Our in-depth analysis of the forecasted sales data of REZAFUNGIN from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REZAFUNGIN.

Key Questions:

• Which company is developing REZAFUNGIN along with the phase of the clinical study?
• What is the technology utilized in the development of REZAFUNGIN?
• What is the product type, route of administration and mechanism of action of REZAFUNGIN?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REZAFUNGIN development?
• What are the key designations that have been granted to REZAFUNGIN?
• What is the forecasted market scenario of REZAFUNGIN?
• What is the history of REZAFUNGIN and what is its future?
• What is the forecasted sales of REZAFUNGIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to REZAFUNGIN?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

• 1.1. Product Detail
• 1.2. Mechanism of Action
• 1.3. Dosage and Administration
• 1.4. Research and development activity
  • 1.4.1. Clinical Development
  • 1.4.2. Safety and Efficacy
• 1.5. Other Development Activities

2. Market Assesment

• 2.1. 7MM Market Analysis
• 2.2. The United States Market
• 2.3. Germany Market
• 2.4. France Market
• 2.5. Italy Market
• 2.6. Spain Market
• 2.7. United Kingdom Market
• 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

• Table 1 REZAFUNGIN, Description
• Table 2 REZAFUNGIN, Clinical Trial Description
• Table 3 REZAFUNGIN, 7MM Market Size from 2020 to 2030 (in Million USD)
• Table 4 Market Competitors
• Table 5 Other Emerging Therapies

List of Figures

• Figure 1 The Development Timeline of REZAFUNGIN
• Figure 2 Patent Details, REZAFUNGIN
• Figure 3 REZAFUNGIN, 7MM Market Size from 2020 to 2030 (in Million USD)
• Figure 4 REZAFUNGIN, US Market Size from 2020 to 2030 (in Millions USD)
• Figure 5 REZAFUNGIN, EU5 Market Size from 2020 to 2030 (in Millions USD)
• Figure 6 REZAFUNGIN, Japan Market Size from 2020 to 2030 (in Millions USD)